X4 Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
XFOR$3.33+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. FINANCIAL STATEMENTS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(unaudited)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,257 | $55,699 |
| Accounts receivable | 509 | 1,070 |
| Marketable securities | 46,694 | 46,361 |
| Research and development incentive receivable | 665 | 640 |
| Inventory | 3,089 | 2,817 |
| Prepaid expenses and other current assets | 4,483 | 5,588 |
| Total current assets | 95,697 | 112,175 |
| Property and equipment, net | 487 | 776 |
| Goodwill | 17,351 | 17,351 |
| Intangible asset, net | 9,813 | 10,000 |
| Right-of-use assets | 3,652 | 4,065 |
| Other assets | 3,013 | 2,080 |
| Total assets | $130,013 | $146,447 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $11,115 | $8,621 |
| Accrued expenses (Note 9) | 12,611 | 23,005 |
| Deferred revenue | 855 | — |
| Current portion of lease liability | 1,303 | 1,251 |
| Total current liabilities | 25,884 | 32,877 |
| Long-term debt, including accretion, net of discount (Note 10) | 75,629 | 75,425 |
| Lease liabilities | 1,109 | 1,410 |
| Warrant liability (Note 5) | 2,925 | 13,755 |
| Deferred revenue | 955 | — |
| Other liabilities | 567 | 831 |
| Total liabilities | 107,069 | 124,298 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value. 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.001 par value, 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; 5,788,745 and 5,698,231 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 6 | 6 |
| Additional paid-in capital | 538,139 | 537,620 |
| Accumulated other comprehensive loss | (128) | (122) |
| Accumulated deficit | (515,073) | (515,355) |
| Total stockholders’ equity | 22,944 | 22,149 |
| Total liabilities and stockholders’ equity | $130,013 | $146,447 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.